Deinove S.A. (Euronext Growth: ALDEI.PA)

https://www.deinove.com

LinkedIn: https://linkedin.com/company/deinove

DEINOVE is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed. This breakthrough approach gave birth to one of the World first specialized micro-biotechnology platforms and a unique collection of 10,000 rare strains and thousands of bacterial extracts. Nowadays, DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, one of the World primary emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis. Based at the heart of the Euromédecine park in Montpellier, DEINOVE is listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056) since 2010. The Company has more than 50 employees and leans on a world class network of academic, technological, industrial and institutional partners. *

	Start	2006-12-01 established (approx)
	Industry	BIOTECH
	Industry 2	biofuel
	Person	Rideau, Alexis (Deinove 20205– CEO before BIOASTER)
	Person 2	Pouletty, Philippe (Truffle Capital 201508 General Partner + Deinove Chairman)

	Region	Paris
	Country	France
	Street	1682 rue de la Valsière Cap Sigma / ZAC Euromédecine II
	City	34790 Grabels
	Tel	+33-4-4819-0100
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2017-12-31)
	Currency	EUR
	Annual sales	214,000 (revenue, operating, total, consolidated (2017) 2017-12-31)
	Profit	-7,335,000 (2017-12-31)
	Cash	4,876,000 (2017-12-31)

		* Document for »About Section«: Deinove S.A.. (1/11/21). "Press Release: Alexis Rideau Appointed CEO of Deinove". Montpellier.

		Record changed: 2024-02-12